Managing Toxicities of BRAF-MEK Inhibitors in Non-Small Cell Lung Cancer – Dr. Melissa Johnson

BRAF V600E mutated non-small cell lung cancer treatment requires navigating the choice between BRAF-MEK inhibitor combinations and chemoimmunotherapy. Dr. Melissa Johnson, a thoracic medical oncologist, highlights that while the Dabrafenib and Trametinib regimen is well-established, Encorafenib and Binimetinib is increasingly favored for its superior tolerability and robust clinical data, including a median progression-free survival of 30.2 months and an overall survival of 47.6 months in the PHAROS study. Managing treatment toxicities necessitates proactive strategies, such as dose-reducing the MEK inhibitor first when adverse events like GI distress or cardiac issues arise. While targeted therapy remains the preferred first-line approach due to its oral administration, clinicians must remain vigilant regarding side effects like pyrexia and pneumonitis, keeping chemoimmunotherapy as a critical alternative when targeted options are no longer effective or are poorly tolerated by the patient.